Romy Elise van Weelderen, Christine J Harrison, Kim Klein, Yilin Jiang, Jonas Abrahamsson, Todd Alonzo, Richard Aplenc, Nira Arad-Cohen, Emmanuelle Bart-Delabesse, Barbara Buldini, Barbara De Moerloose, Michael N Dworzak, Sarah Elitzur, José M Fernández Navarro, Alan S Gamis, Robert B Gerbing, Bianca F Goemans, Hester A de Groot-Kruseman, Erin M Guest, Shau Yin Ha, Henrik Hasle, Charikleia Kelaidi, Helene Lapillonne, Guy Leverger, Franco Locatelli, Takako Miyamura, Ulrika Noren-Nystrom, Sophia Polychronopoulou, Mareike Rasche, Jeffrey E Rubnitz, Jan Stary, Anne Tierens, Daisuke Tomizawa, Michel C Zwaan, Gertjan J L Kaspers
Comprehensive international consensus on cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Study Group study on 1,256 children with KMT2A-r AML aimed to validate the prognostic value of established recurring KMT2A fusions and additional cytogenetic aberrations (ACAs), and secondly, to define additional, recurring KMT2A fusions and ACAs, evaluating their prognostic relevance...
April 15, 2024: Blood Advances